Skip to content


Solid cash position of €24.7 million and finalization of CARAT phase 2 clinical study

Toulouse, France, Ann Arbor, United States, February 17 2017 – 6 pm CET – Cerenis Therapeutics (FR0012616852- CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (“good cholesterol”) for treating cardiovascular and metabolic diseases, today announces its full-year 2016 financial results, as approved by the Board of Directors on February 17 2017. Audit procedures on statutory and consolidated accounts have been performed by the auditors and certification report is currently being issued.

Read the Full-year 2016 financial results,

Soruce: Cerenis